Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery.
Conferences
Levy, JH; Despotis, GJ; Olson, P; Weisinger, A; Szlam, F; Meeker, DP
Published in: BLOOD
November 15, 1997
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 15, 1997
Volume
90
Issue
10
Start / End Page
1318 / 1318
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Levy, J. H., Despotis, G. J., Olson, P., Weisinger, A., Szlam, F., & Meeker, D. P. (1997). Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. In BLOOD (Vol. 90, pp. 1318–1318).
Levy, J. H., G. J. Despotis, P. Olson, A. Weisinger, F. Szlam, and D. P. Meeker. “Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery.” In BLOOD, 90:1318–1318, 1997.
Levy JH, Despotis GJ, Olson P, Weisinger A, Szlam F, Meeker DP. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. In: BLOOD. 1997. p. 1318–1318.
Levy, J. H., et al. “Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery.” BLOOD, vol. 90, no. 10, 1997, pp. 1318–1318.
Levy JH, Despotis GJ, Olson P, Weisinger A, Szlam F, Meeker DP. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. BLOOD. 1997. p. 1318–1318.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 15, 1997
Volume
90
Issue
10
Start / End Page
1318 / 1318
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology